A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad102 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Nicholas P Wayham und 19 weiteren Autor:innen. Beteiligte Einrichtung: GigaGen, Inc. (A Grifols Company), San Carlos, California, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GigaGen, Grifols.
Abstract (Originalsprache)
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) possess mutations that prevent antibody therapeutics from maintaining antiviral binding and neutralizing efficacy. Monoclonal antibodies (mAbs) shown to neutralize Wuhan-Hu-1 SARS-CoV-2 (ancestral) strain have reduced potency against newer variants. Plasma-derived polyclonal hyperimmune drugs have improved neutralization breadth compared with mAbs, but lower titers against SARS-CoV-2 require higher dosages for treatment. We previously developed a highly diverse, recombinant polyclonal antibody therapeutic anti-SARS-CoV-2 immunoglobulin hyperimmune (rCIG). rCIG was compared with plasma-derived or mAb standards and showed improved neutralization of SARS-CoV-2 across World Health Organization variants; however, its potency was reduced against some variants relative to ancestral, particularly omicron. Omicron-specific antibody sequences were enriched from yeast expressing rCIG-scFv and exhibited increased binding and neutralization to omicron BA.2 while maintaining ancestral strain binding and neutralization. Polyclonal antibody libraries such as rCIG can be utilized to develop antibody therapeutics against present and future SARS-CoV-2 threats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GigaGen, Inc. (A Grifols Company), San Carlos, California, USA.
ORCID-Profile: Sheila M Keating
Förderung
- GigaGen
- Grifols
Zitieren
APA
Wayham, N. P., Niedecken, A. R., Simons, J. F., Chiang, Y. Y., Medina-Cucurella, A. V., Mizrahi, R. A., Wagner, E. K., Gras, A., Segal, I., Witte, P., Enstrom, A., Bountouvas, A., Nelson, S. M., Weinberger, T., Tan, D., Asensio, M. A., Subramanian, A., Lim, Y. W., Adler, A. S., & Keating, S. M. (2023). A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad102
Vancouver
Wayham NP, Niedecken AR, Simons JF, Chiang YY, Medina-Cucurella AV, Mizrahi RA, et al. A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad102
BibTeX
@article{Wayham2023,
author = {Wayham, Nicholas P and Niedecken, Ariel R and Simons, Jan Fredrik and Chiang, Yao Y and Medina-Cucurella, Angélica V and Mizrahi, Rena A and Wagner, Ellen K and Gras, Ashley and Segal, Ilana and Witte, Peyton and Enstrom, Alexis and Bountouvas, Aristea and Nelson, Sabrina M and Weinberger, Tess and Tan, David and Asensio, Michael A and Subramanian, Alagu and Lim, Yoong Wearn and Adler, Adam S and Keating, Sheila M},
title = {A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad102}
}
EUVIMED